Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...

Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12.89 billion in 2025 to USD 25.38 billion by 2033, growing at a CAGR of 8.84 ...

The artificial intelligence community is raving over a new reasoning model that has surprised even Silicon Valley.

This application note presents a method that integrates protein elimination and free drug identification into one analysis using a two-dimensional liquid chromatography/quadrupole time-of-flight mass ...

A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing deals. | A year after going public, ArriVent BioPharma is continuing to ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, including ...

US clinical-stage biotech ArriVent BioPharma has entered into an exclusive license agreement with Shanghai-based Lepu Biopharma for MRG007, an antibody-drug conjugate (ADC) that can target several ...